Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Julie Burek - Vice President of Finance Dr. Al Sandrock - Chief Financial Officer Dr. Todd Carter - Senior Vice President of Research Conference Call Participants Jack Allen - Baird Divya Rao - Cowen & Company Yung Zhong - BTIG Operator Good day, and welcome to Voyager Therapeutics Second Quarter 2022 Conference Call. All participants are now in a listen-only mode. There will be a question ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-3003182 (S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ______ to ______ Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-300318 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-3003182 (State o ...

Dated February 18, 2022 © Voyager Therapeutics © Voyager Therapeutics UNLOCKING THE POTENTIAL OF AAV GENE THERAPY Corporate Presentation | February 2022 Forward-Looking Statements This presentation, posted to the Company's website on December 10, 2021, contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "might," "will," "should," "expect," "plan," "anti ...

Table of Contents FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission file number: 001-37625 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) For the quarterly period ended September 30, 2021 Delaware 46-3003182 (State or other jurisdiction of incorporation or organization) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC ...

Company Highlights - Voyager Therapeutics is focused on delivering the next generation of gene therapies[1] - The company is extending its cash runway into early 2023[5] Technology Platform - Voyager Therapeutics utilizes proprietary AAV capsids to power second-generation efforts in Huntington's disease and ALS, and pre-clinical programs in spinal muscular atrophy and diseases linked to GBA1 mutations[5] - The company is increasing platform investment to expand discovery of novel targeted AAV capsids and clinical application of vectorized antibodies[5] - TRACER AAV capsids offer superior transduction of targeted tissues enabling lower dose GTx using IV delivery to target CNS, cardiac, and skeletal muscle[7] - The company's vectorized mAb platform aims to achieve therapeutic antibody levels to CNS via IV delivery to overcome very low CNS penetration of traditional mAbs, with preclinical POC demonstrated with an anti-tau program and exploration into neuro-oncology indication[7] - Voyager Therapeutics is advancing best-in-class GTxs leveraging superior TRACER capsids across CNS indications, potentially allowing for IV administration, lower dosing, favorable safety, and superior CNS tissue distribution[7] - Multiple candidates show a 10-1000-fold improvement in CNS & spinal cord transduction compared to AAV9[10]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-3003182 ( ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2021. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ______ to ______ Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-300318 ...

Call Start: 16:30 January 1, 0000 5:07 PM ET Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2020 Earnings Conference Call February 25, 2021 16:30 ET Company Participants Allison Dorval - Chief Financial Officer Andre Turenne - President & Chief Executive Officer Omar Khwaja - Chief Medical Officer & Head of R&D Conference Call Participants Phil Nadeau - Cowen Ken Shields - Wedbush Hannah Latimer - Morgan Stanley Aydin Huseynov - Benchmark Operator Good afternoon, and welcome to the Voyager Therapeutics Fourth ...